# BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

> **NCT04563195** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Matthew C. Baker**

## Conditions studied

- Primary Sjogren's Syndrome

## Interventions

- **DRUG:** tibulizumab (LY3090106)

## Key facts

- **NCT ID:** NCT04563195
- **Lead sponsor:** Matthew C. Baker
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-01
- **Primary completion:** 2023-12
- **Final completion:** 2025-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug unavailable
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563195, "BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04563195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*